Dulaglutide

The FDA has confirmed there is no longer a shortage of tirzepatide and has set dates for companies to cease distribution of compounded forms of the agent, according to an announcement from the agency.

Shortages of tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, have been resolved, the FDA announced.

A once-weekly GLP-1/glucagon dual agonist conferred greater decreases in HbA1c and body weight than the GLP-1 receptor agonist dulaglutide for adults with type 2 diabetes, according to a presenter.

SGLT2 inhibitors and dulaglutide confer a similar risk for dementia among adults aged 60 years and older with type 2 diabetes, according to findings published in Annals of Internal Medicine.

Although glucagon-like peptide-1 receptor agonist use prior to upper endoscopy was linked to a higher rate of retained gastric contents, evidence supports prolonged fasting as the “optimal approach” rather than routine discontinuation.

BOSTON — From 2019 to 2023, insurance covered GLP-1 receptor agonist prescriptions at a Texas hospital for less than 70% of young people with type 2 diabetes and less than 40% of those with obesity.

Tirzepatide and injectable semaglutide were associated with the greatest weight loss after a year of treatment among several GLP-1 receptor agonists, a recent study showed.

Women who quit smoking and were treated with the GLP-1 receptor agonist dulaglutide were less likely to experience substantial weight gain compared with those who received placebo, according to researchers.

Semaglutide conferred greater reductions in HbA1c and body weight among adults with type 2 diabetes than other GLP-1 receptor agonists, according to findings from a systematic review and meta-analysis.

Pharmaceutical executives fielded questions on the costs of insulin and other prescription drugs during a recent hearing of the U.S. Senate Committee on Health, Education, Labor and Pensions.